NEWARK, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the closing of its follow-on public offering of 4,600,000 shares of common stock at a public offering price of $30.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 600,000 additional shares of common stock at the same price. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expense payable by Revance Therapeutics will be approximately $131.3 million.
Cowen and Company and Piper Jaffray acted as joint book-running managers for the offering, with BMO Capital Markets and William Blair acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 18, 2014. The offering was made only by means of a prospectus, which is part of the effective registration statement. A copy of the final prospectus relating to the offering may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140; or Piper Jaffray & Co., 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, Telephone: 800-747-3924, Email: email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Revance Therapeutics, Inc.
Revance is a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and therapeutic indications. Revance has developed a platform technology, TransMTS®, which enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.
Westwicke Partners, Investor Relations Lynn Pieper 415-202-5678 firstname.lastname@example.org